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Dear Sirs,
A 13-year-old girl was seen at the Neurology and Med-
ical Genetics Clinics with delayed milestones, macro-
cephaly and developmental regression. She had no history
of perinatal complications other than delivery via cesarean
section because of breech presentation. Over the preceding
2 years she had developed nystagmus, occurring 4–5 times
a week. She had staring spells but had a normal EEG. Her
milestones, which included standing at 18 months of age,
first words at 2 years of age, walking at 2 years of age,
and writing letters at 6–7 years of age, were delayed. Her
developmental regression included enuresis, day time loss
of bladder control and use of incorrect words for identifi-
cation. Her gait had become unsteady, speech less under-
standable because of mumbling, and she experienced
intermittent difficulty in recognizing her mother. Her
family history was unremarkable with no consanguinity.
On examination she had macrocephaly, mild facial coars-
ening, thick eye brows, dark coarse hair, mild synophrys,
thick lips, high arched palate, low anterior and posterior
hairline, intermittent tonic up gaze, nystagmus, and hypo-
tonia with normal muscle bulk. MRI of the brain (Fig. 1)
showed enlarged extra-axial spaces, hypoplastic temporal
lobes, open Sylvian fissures, mild ventriculomegaly and
enlarged perivascular spaces. Skeletal survey was normal.
Additional laboratory work up including lactic acid,
pyruvic acid, mitochondrial respiratory enzyme analysis,
CoQ10 levels, neurotransmitter profile (5-methyltetrahy-
drofolate, 5-hydroxyindoleacetic acid, homovanillic acid,
3-O-methyldopa, neopterin, tetrahydrobiopterin, succinyl-
adenosine and pyridoxal 5 phosphate), karyotype, chro-
mosomal microarray (44K custom Agilent platform),
plasma amino acids and acylcarnitine profile was normal.
Urine organic acid analysis revealed significant 2-hydrox-
yglutaric aciduria, which was confirmed to be the D-enan-
tiomer by a LC–MS/MS method that separates D- from the
L-enantiomer [1]. Enzyme analysis on skin fibroblast cul-
tures showed severely deficient D-2-hyroxyglutarate dehy-
drogenase activity. Two disease causing mutations
(c.373G[A and c.858C[A) were found in the D2HGDH
gene. A urine mucopolysaccharidosis (MPS) screen com-
pleted during her initial evaluation showed increased hep-
arin sulfate (HS), suggesting co-morbidity with Sanfilippo
syndrome. Further investigation showed alpha-glucosami-
nide N-acetyltransferase deficiency and heterozygosity for
two disease causing mutations in the HGSNAT gene: a
splicing mutation defined as c.372-2A[G and a nonsense
mutation defined as c.1516C[T.
Sanfilippo Syndrome is the most common of MPS dis-
orders. It is caused by deficiency or absence of any one of
the four different enzymes that are necessary to degrade the
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glycosaminoglycan, HS, leading to its accumulation in a
variety of tissues. Manifestations include mildly coarse
facial features, synophrys, mild hepatosplenomegaly, mild
dysostosis multiplex and severe progressive neurologic
degeneration. Neurodegeneration ultimately leads to a
vegetative state [2]. MRI findings include cerebral atrophy,
abnormal or delayed myelination and dilatation of peri-
vascular spaces [3]. Over time, airway obstruction and/or
pulmonary infection can lead to cardiopulmonary arrest. A
subtype, Sanfilippo type C syndrome is caused by defi-
ciency of alpha-glucosamine N-acetyltransferase encoded
by HGSNAT [4]. No disease-modifying treatment is pres-
ently available. Supportive treatment is aimed at improving
quality of life.
D-2-hydroxyglutaric aciduria is a rare neurometabolic
disorder and organic acidemia characterized by varied
clinical symptoms [5]. Clinical presentations vary from
asymptomatic to developmental delay, epilepsy, hypotonia,
dysmorphic features, neonatal- or early-infantile-onset
epileptic encephalopathy, cerebral visual failure and car-
diomyopathy. Delayed cerebral maturation, ventricular
white-matter abnormalities and subependymal cysts are
seen on MRI of the brain. Patients with D-2-hydroxyglu-
taric aciduria have been found to be homozygous or
compound heterozygous for mutations in D2HGDH
encoding D-2-hydroxyglutarate dehydrogenase or hetero-
zygous for mutations in IDH2 encoding isocitrate dehy-
drogenase-2 [6]. No disease-modifying treatment is
currently available.
Both of these diseases are characterized by a neurologic
phenotype [2, 7]. They are very rare and the likelihood of
them occurring together is extremely remote, especially in
non-consanguineous unions. Hence, identifying one rare
metabolic disorder may induce the physician to stop further
diagnostic assessment. Our case demonstrates the need
to look further when the phenotype is not completely
explained by the disorder detected by laboratory investi-
gation. The physical examination, the unusual MRI find-
ings and an abnormal MPS screen, prompted us to pursue
further testing. This case demonstrates the challenges
involved in diagnosing rare inborn metabolic disease and
correlating discordant laboratory findings with clinical
symptoms. An exact and complete genetic diagnosis is
essential to providing an accurate prognosis for this patient
and for counseling family members.
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